Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Constructing a synthetic metabolic pathway in Escherichia coli to produce the enantiomerically pure (R, R)‐2,3‐butanediol

Constructing a synthetic metabolic pathway in Escherichia coli to produce the enantiomerically... ABSTRACT Enantiomerically pure (R, R)‐2,3‐butanediol has unique applications due to its special chiral group and spatial configuration. Currently, its chemical production route has many limitations. In addition, no native microorganisms can accumulate (R, R)‐2,3‐butanediol with an enantio‐purity over 99%. Herein, we constructed a synthetic metabolic pathway for enantiomerically pure (R, R)‐2,3‐butanediol biosynthesis in Escherichia coli. The fermentation results suggested that introduction of the synthetic metabolic pathway redistributed the carbon fluxes to the neutral (R, R)‐2,3‐butanediol, and thus protected the strain against the acetic acid inhibition. Additionally, it showed that the traditionally used isopropyl beta‐D‐thiogalactoside (IPTG) induction displayed negative effect on (R, R)‐2,3‐butanediol biosynthesis in the recombinant E. coli, which was probably due to the protein burden. With no IPTG addition, the (R, R)‐2,3‐butanediol concentration reached 115 g/L by fed‐batch culturing of the recombinant E. coli, with an enantio‐purity over 99%, which is suitable for the pilot‐scale production. Biotechnol. Bioeng. 2015;112: 1056–1059. © 2014 Wiley Periodicals, Inc. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Biotechnology and Bioengineering Wiley

Constructing a synthetic metabolic pathway in Escherichia coli to produce the enantiomerically pure (R, R)‐2,3‐butanediol

Loading next page...
 
/lp/wiley/constructing-a-synthetic-metabolic-pathway-in-escherichia-coli-to-3SlaE8xQgB

References (20)

Publisher
Wiley
Copyright
© 2015 Wiley Periodicals, Inc.
ISSN
0006-3592
eISSN
1097-0290
DOI
10.1002/bit.25512
pmid
25450449
Publisher site
See Article on Publisher Site

Abstract

ABSTRACT Enantiomerically pure (R, R)‐2,3‐butanediol has unique applications due to its special chiral group and spatial configuration. Currently, its chemical production route has many limitations. In addition, no native microorganisms can accumulate (R, R)‐2,3‐butanediol with an enantio‐purity over 99%. Herein, we constructed a synthetic metabolic pathway for enantiomerically pure (R, R)‐2,3‐butanediol biosynthesis in Escherichia coli. The fermentation results suggested that introduction of the synthetic metabolic pathway redistributed the carbon fluxes to the neutral (R, R)‐2,3‐butanediol, and thus protected the strain against the acetic acid inhibition. Additionally, it showed that the traditionally used isopropyl beta‐D‐thiogalactoside (IPTG) induction displayed negative effect on (R, R)‐2,3‐butanediol biosynthesis in the recombinant E. coli, which was probably due to the protein burden. With no IPTG addition, the (R, R)‐2,3‐butanediol concentration reached 115 g/L by fed‐batch culturing of the recombinant E. coli, with an enantio‐purity over 99%, which is suitable for the pilot‐scale production. Biotechnol. Bioeng. 2015;112: 1056–1059. © 2014 Wiley Periodicals, Inc.

Journal

Biotechnology and BioengineeringWiley

Published: May 1, 2015

There are no references for this article.